Low-dose enzalutamide for metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial looks at how well a lower dose of the drug enzalutamide works and how tolerable it is for men with prostate cancer that has spread. It may help doctors understand if a lower dose can be effective with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Prostate cancer that has spread to other parts of the body (metastatic)
- You were treated with enzalutamide between August 2014 and December 2023
- You are at least 18 years old
- You are willing to sign a consent form
- You do not have serious heart problems (like heart failure or recent heart attack)
- You are not taking enzalutamide if you died within the first month of starting it (this is not an issue for living patients)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding specific antibiotics (amoxicillin, metronidazole, vancomycin, ciprofloxacin) to enzalutamide can help treat advanced prostate cancer that has stopped responding to other treatments. It aims to see if changing gut bacteria can make the cancer therapy work better.
This study tests whether a lower dose of enzalutamide works as well for men aged 75 and older with advanced prostate cancer, potentially reducing side effects. Participants will receive enzalutamide alongside hormone therapy and be monitored closely.
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
This Phase 1 trial tests a new medicine (TVB-2640) combined with enzalutamide in men with prostate cancer that has spread and is no longer responding to hormone treatment. It aims to find a safe dose and see how well the treatment can work against the cancer.
This study tests whether a shorter course of a newer hormone pill (apalutamide or enzalutamide) works well for men whose prostate cancer has spread to just a few spots and who recently started standard hormone therapy. It may allow you to take medication for less time while still controlling the cancer.
Hear when a new Prostate Cancer Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.